<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678300</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-000100</org_study_id>
    <nct_id>NCT01678300</nct_id>
  </id_info>
  <brief_title>Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)</brief_title>
  <official_title>Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is:&#xD;
&#xD;
        1. To quantify the prevalence of adherence to topical mesalamine in patients with UC&#xD;
&#xD;
        2. To describe the determinants of medication adherence in patients with UC prescribed&#xD;
           topical mesalamine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient adherence with topical mesalamine is low. Behavioral and psycho-social barriers to&#xD;
      topical mesalamine adherence exist in patients with UC. These factors can be identified using&#xD;
      qualitative testing in order to develop and design appropriate behavioral interventions to&#xD;
      reduce non-adherence.&#xD;
&#xD;
      The investigators will undertake an observational study of medication persistence in 100&#xD;
      patients in the BIDMC clinic, &quot;Persistence Cohort&quot;. Persistence will be measured using&#xD;
      12-month pharmacy refill data. The investigators will also employ a qualitative research&#xD;
      design with discrete choice modeling in two phases: Phase I - Initial Interviews with 10&#xD;
      patients and Phase II - Focus Groups (2) with 5 patients each.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of &quot;non-persistence&quot; amongst patients prescribed topical mesalamine for UC</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (remission / relapse) at 12 months grouped by persistence status</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical outcome (remission / relapse) based on Simple Colitis Activity Index Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence phenotype details</measure>
    <time_frame>12 months</time_frame>
    <description>Prevalence of self-reported &quot;low adherence&quot; amongst patients prescribed topical mesalamine&#xD;
Demographic and disease phenotype variables associated with &quot;non persistence&quot; or &quot;low adherence&quot; using multivariate logistic regression analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life score at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Short Inflammatory Bowel Disease Questionnaire score at 12 months</description>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Ulcerative Colitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The population of this study will be adults with diagnosed Ulcerative Colitis who have been&#xD;
        prescribed topical mesalamine (Rowasa/Canasa) for treatment of their ulcerative colitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must have ulcerative colitis diagnosed by a doctor at least 1 month prior to study&#xD;
             participation&#xD;
&#xD;
          -  must be prescribed topical mesalamine (e.g. Rowasa enemas or Canasa suppositories) by&#xD;
             a doctor&#xD;
&#xD;
          -  must be receiving care at Beth Israel Deaconess Medical Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no diagnosis of ulcerative colitis&#xD;
&#xD;
          -  no prescription for topical mesalamine&#xD;
&#xD;
          -  not receiving care at Beth Israel Deaconess Medical Center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan C Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Alan C. Moss</investigator_full_name>
    <investigator_title>Director of Translational Research, Inflammatory Bowel Disease Center</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

